In Silico Discovery Meets Empirical Discovery
We Design
We explore our proprietary 1859 virtual library for a specific disease target and then design focused libraries of small molecules predicted to affect that target in a desired way.
We Build
We construct the focused libraries of small molecules for testing in a matter of weeks.
We Test
We screen focused libraries in a biochemical or cell based context at the pico-scale, with a few milliliters of materials.
We Learn
We discover the identity of the molecules that affected the disease target, and then leverage machine learning and AI to design new focused libraries predicted to produce even better discoveries.
We offer the ability to navigate chemical space unimpeded by the capital and time constraints of the status quo, giving our partners access to the right type of chemical matter from the start of a discovery program. We use both structure-based and ligand-based virtual screening methods to identify the right properties of the molecules needed to affect a particular disease target. Lastly, we offer the ability to screen our growing inventory of Training Set Libraries designed to tease out the types of molecules we should include in a subsequent library design.
21
Active Programs
320k
Molecules per Week Screened
3 weeks
for New Library Build
4 mL
of Material per Screen
We are opening up our technology and capabilities to partners looking to join our revolution on upending the current paradigm for new medicine discovery.
Let's Partner
We are building the tools that will make the discovery of new medicines a data science.
Join Us
Our Blog –
